-

US Supreme Court rules in favor of Monsanto in the Durnell case

LEVERKUSEN, Germany--(BUSINESS WIRE)--The U.S. Supreme Court decision is good for science, farmers, and industries that depend on regulatory clarity for innovation. It should help significantly contain the Roundup™ litigation after nearly a decade of legal battles. The ruling should result in the dismissal of current warning-based claims and bar future failure-to-warn claims.

Monsanto will continue to pursue final approval of the class settlement and other elements of its multi-pronged strategy to contain the Roundup™ litigation.

The company is still reviewing the U.S. Supreme Court’s ruling and will provide a more comprehensive statement shortly.

pb (2026-0106E)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

Bayer AG is a holding company with operating subsidiaries worldwide. References to “Bayer” or “the company” herein may refer to one or more subsidiaries as context requires.

Contacts

Contact for media inquiries:
Brian Leake, phone +1 314.370.3285
Email: brian.leake@bayer.com

Philipp Blank, phone +49 214 30-20499
Email: philipp.blank@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team

Find more information at www.bayer.com.

Bayer AG


Release Versions

Contacts

Contact for media inquiries:
Brian Leake, phone +1 314.370.3285
Email: brian.leake@bayer.com

Philipp Blank, phone +49 214 30-20499
Email: philipp.blank@bayer.com

Contact for investor inquiries:
Bayer Investor Relations Team, phone +49 214 30-72704
Email: ir@bayer.com
www.bayer.com/en/investors/ir-team

Find more information at www.bayer.com.

More News From Bayer AG

Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack...

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Bayer’s SUNHARBO® (asundexian), 50 mg tablets, the First and Only Factor XIa Inhibitor, Approved by the U.S. FDA to Reduce the Risk of Stroke in Adults With Recent Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, in Combination With Antiplatelet Therapy Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved SUNHARBO® (asundexian), 50 mg tablets, a first-in-class, once daily, Factor XIa inhibitor indicat...

Bayer and America’s Grow-a-Row Continue Partnership to Fight Food Insecurity

PITTSTOWN, N.J.--(BUSINESS WIRE)--In 2026, Bayer and America’s Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce for communities across the United States. Key Facts More than 200 Bayer employees volunteered with America’s Grow-a-Row on August 27 and October 1. Volunteers harvested 165,500 pounds of produce, equivalent to approximately 662,000 servings. Since 2020, Bayer Fund has provided more than $500,000 in grants to A...

Bayer to Present New Cardiovascular, Kidney and Stroke Data at the 2026 American Heart Association (AHA) Scientific Sessions

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer today announced that new data from its cardiovascular, kidney and stroke portfolios will be featured at the American Heart Association Scientific Sessions in Chicago, Illinois from November 6-9, 2026. Key Facts A late-breaking oral presentation will feature data from an exploratory post-hoc analysis of the Phase 3 OCEANIC-STROKE study, which evaluated asundexian versus placebo, both in combination with antiplatelet therapy, in patients after...
Back to Newsroom